Danish drugmaker Lundbeck sees strong first-half growth driven by migraine and depression treatments

Danish pharmaceutical firm Lundbeck has announced strong financial results for the first half of 2026, with total revenue climbing to 13.6 billion Danish kroner, an increase of nearly 11 percent compared to the same period last year.

The company, which specializes in treatments for brain diseases including migraine, epilepsy, depression, anxiety, Huntington's disease, and Alzheimer's disease, saw significant growth driven by its migraine medication Vyepti. Sales of Vyepti surged by 36 percent, reaching nearly 2.9 billion kroner.

Another key contributor to Lundbeck's performance was Rexulti, a drug used to treat depression and dementia, as well as schizophrenia. Rexulti generated 3.3 billion kroner in sales, marking an eight percent increase. The majority of Lundbeck's revenue originates from the American and European markets, with the United States being the primary driver of growth in the first half of the year.

Charl van Zyl, CEO of Lundbeck, described the commercial results as "strong." He expressed confidence in the company's strategic direction, stating, "With a strong balance sheet and clear strategic progress, we enter the next phase of our strategy with confidence."

Founded in 1915 by Hans Lundbeck, the company initially operated as a trading firm dealing in diverse goods. It began producing and packaging pharmaceuticals in Denmark in the 1930s. Today, Lundbeck operates production facilities in Denmark, France, and Italy, alongside research centers in Denmark and the United States.